profit from every $100 of sales.
$0$100
Beta Bionics
$16.51-7.30% today
-47.5% in 1 year
1-year low $8.861-year high $31.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Beta Bionics sold, what it kept, and what it did with the cash.
Sales went from $179,000 in 2022 to $100 million in 2025, with -$73.2 million of profit last year.
SalesProfit
Beta Bionics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Beta Bionics | No profit yet | ||
 Concentra Group Holdings Parent | 32.5× · Expensive | ||
 Hims & Hers Health | 36.0× · Expensive | ||
 Envista | 84.1× · Very expensive | ||
 CapsoVision | No profit yet |
AI analysis
An AI analyst reads Beta Bionics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 12 | 65 | 100 | |
| 0 | 6 | 36 | 56 | |
| -66 | -36 | -45 | -72 | |
| -63 | -34 | -43 | -69 | |
| -65 | -44 | -55 | -73 | |
| -2.12 | -1.45 | -1.28 | -1.81 | |
| 100.0% | 52.6% | 55.1% | 55.4% | |
| -36,784.4% | -298.9% | -69.5% | -71.5% | |
| -36,173.7% | -367.6% | -84.1% | -73.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 36 | 110 | 150 | 329 |
| Cash | 28 | 27 | 30 | 32 |
| Total debt | 4 | 4 | 7 | 7 |
| Total liabilities | 206 | 313 | 395 | 41 |
| -170 | -203 | -245 | 288 | |
| 30 | 30 | 43 | 41 | |
| – | – | – | -19.2% | |
| 38.1% | 21.7% | 22.3% | -25.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -60 | -32 | -48 | -51 | |
| 1 | 0 | 3 | 5 | |
| -61 | -33 | -52 | -56 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 6 | 6 | 16 |
Valuation
- –
- –
- –
- 1.5×
- 9.0×
- –
- –
- -6.3%
- -8.2%
- 0.0%
Profitability
- 55.4%
- -71.5%
- -73.0%
- -63.0%
- -27.3%
- -134.7%
- -23.0%
- -21.8%
- -27.5%
- 34.1%
Growth
- +724.3%
- –
- −8.8%
- –
- +100.9%
Financial health
- -0.4×
- 0.03
- 2.3%
- –
- 10.69
- 9.67
- 0.36
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 952
Bottom 5%of 883
Bottom 16%of 985
What analysts expect
- Average price target
- $21.00
- Range
- $14.00 – $25.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 21, 2026 | -0.49 | -0.53 | +7.5% |
| Feb 17, 2026 | -0.30 | -0.42 | +28.6% |
| Oct 28, 2025 | -0.33 | -0.45 | +26.7% |
| Jul 29, 2025 | -0.39 | -0.51 | +23.5% |
| May 6, 2025 | -0.52 | -0.51 | −2.0% |
| Mar 25, 2025 | -1.82 | -0.42 | −333.3% |
| Jan 31, 2025 | -1.55 | – | – |
| Dec 31, 2023 | -3.13 | – | – |
News
S&P 500 Just Wiped Out $3 Trillion: Why This 0.35-Beta Stock is a Safe HavenYahoo Finance · Nov 9, 2026Forget the High-Beta Hype: 5 ‘Sleep Well at Night’ Stocks to Buy NowYahoo Finance · Nov 8, 2026BETA Technologies, Inc. Q3 2026 Earnings PreviewSeeking Alpha · Nov 2, 2026WSFS outlines 45%-50% deposit beta in current hiking cycle while targeting double-digit Walton Trust growthSeeking Alpha · Oct 23, 2026Want to bet on risky, high-beta stocks? Why you should wait for mid-October.MarketWatch · Sep 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
59No pass
Philip Fisher
48No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
39No pass
Terry Smith
35No pass
Questions about Beta Bionics
Is Beta Bionics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Beta Bionics AI analysis
What does Beta Bionics do?
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It is in Medical - Equipment & Services.
Does Beta Bionics pay a dividend?
No. Beta Bionics does not pay a dividend at the moment.
Is Beta Bionics stock halal?
Yes. Beta Bionics passes our halal screen: its business is permitted and its debt is 0.8% of its market value, under the 30% limit. How we check
How has Beta Bionics stock done over the past year?
Down 47.5% over the past twelve months, to $16.51. It traded between $8.86 and $31.99 and is 48.4% below its high.
Who are Beta Bionics's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Hims & Hers Health, Envista and CapsoVision. The peers table on this page compares their profit, growth and price with Beta Bionics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.